These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 2121082)

  • 1. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.
    Myerburg RJ; Kessler KM; Cox MM; Huikuri H; Terracall E; Interian A; Fernandez P; Castellanos A
    Circulation; 1989 Dec; 80(6):1571-9. PubMed ID: 2480856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for the development of proarrhythmic events.
    Morganroth J
    Am J Cardiol; 1987 Apr; 59(11):32E-37E. PubMed ID: 3107364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of encainide for malignant ventricular arrhythmias.
    Tordjman T; Podrid PJ; Raeder E; Lown B
    Am J Cardiol; 1986 Aug; 58(5):87C-95C. PubMed ID: 3092625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
    Pritchett EL; Wilkinson WE
    Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ventricular arrhythmias in children without structural heart disease with class IC agents as guided by invasive electrophysiology.
    Case CL; Gillette PC
    Am J Cardiol; 1990 Nov; 66(17):1265-6. PubMed ID: 2122708
    [No Abstract]   [Full Text] [Related]  

  • 14. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
    N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms.
    Horowitz LN
    Am J Cardiol; 1986 Aug; 58(5):83C-86C. PubMed ID: 3092624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encainide for refractory ventricular tachyarrhythmia.
    Chesnie B; Podrid P; Lown B; Raeder E
    Am J Cardiol; 1983 Sep; 52(5):495-500. PubMed ID: 6193701
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.